Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component.

摘要

Novel human placenta-derived anticoagulating substances having the following properties: (1) molecular weight of 34,000+/-2,000 determined by SDA-polyacrylamide gel electrphoresis under reduced state (2) isoelectric point of 4.7+/-0.1 determined by isoelectric column electrophoresis using an ampholite (3) stability inactivated by heat treatment at 50 DEG C. to 30 minutes, stable at a pH of 4-10, and stable in plasma at 37 DEG C. for 30 minutes (4) activity capable of prolonging a recalcification time, a prothrombin time, and an activated partial thromboplastin time and (5) the existence of several amino acids including aspartic acid, threonine, serine, and so on are prepared by homogenizing human placenta, subjecting the resulting homogenate to centrifugal separation, extracting an anticoagulating substance from the residue or from a microsome fraction contained in the supernatant with a surface active agent and/or a chelating agent, and purifying and isolating the substance from the extract. The anticoagulating substances have a high anticoagulating activity and exhibit a higher activity in the state where the tissue thromboplastin activity is exacerbated or in the state of exacerbating the coagulation. Hence, the anticoagulant containing the substance as an effective component has reduced side effects and is thus harmless.